Literature DB >> 23530539

Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays.

Martin H van Vliet1, Belinda Dumee, Erik Simons, Lars Bullinger, Konstanze Döhner, Hartmut Döhner, Henk Viëtor, Bob Löwenberg, Peter J M Valk, Erik H van Beers.   

Abstract

Mutations in the gene encoding nucleophosmin (NPM1) carry a prognostic value for patients with acute myeloid leukemia (AML). Various techniques are currently being used to detect these mutations in routine molecular diagnostics. Incorporation of accurate NPM1 mutation detection on a gene expression platform would enable simultaneous detection with various other expression biomarkers. Here we present an array-based mutation detection using custom probes for NPM1 WT mRNA and NPM1 type A, B, and D mutant mRNA. This method was 100% accurate on a training cohort of 505 newly diagnosed unselected AML cases. Validation on an independent cohort of 143 normal-karyotype AML cases revealed no false-negative results, and one false positive (sensitivity 100.0% and specificity 98.7%). Based on this, we conclude that this method provides a reliable method for NPM1 mutation detection. The method can be applied to other genes/mutations as long as the mutant alleles are sufficiently highly expressed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23530539      PMCID: PMC3609607          DOI: 10.1089/gtmb.2012.0344

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  25 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  Dynamic model based algorithms for screening and genotyping over 100 K SNPs on oligonucleotide microarrays.

Authors:  Xiaojun Di; Hajime Matsuzaki; Teresa A Webster; Earl Hubbell; Guoying Liu; Shoulian Dong; Dan Bartell; Jing Huang; Richard Chiles; Geoffrey Yang; Mei-mei Shen; David Kulp; Giulia C Kennedy; Rui Mei; Keith W Jones; Simon Cawley
Journal:  Bioinformatics       Date:  2005-01-18       Impact factor: 6.937

3.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

Authors:  Tatsuya Suzuki; Hitoshi Kiyoi; Kazutaka Ozeki; Akihiro Tomita; Satomi Yamaji; Ritsuro Suzuki; Yoshihisa Kodera; Shuichi Miyawaki; Norio Asou; Kazutaka Kuriyama; Fumiharu Yagasaki; Chihiro Shimazaki; Hideki Akiyama; Miki Nishimura; Toshiko Motoji; Katsuji Shinagawa; Akihiro Takeshita; Ryuzo Ueda; Tomohiro Kinoshita; Nobuhiko Emi; Tomoki Naoe
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

6.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

8.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Authors:  Roel G W Verhaak; Chantal S Goudswaard; Wim van Putten; Maarten A Bijl; Mathijs A Sanders; Wendy Hugens; André G Uitterlinden; Claudia A J Erpelinck; Ruud Delwel; Bob Löwenberg; Peter J M Valk
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

9.  Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Authors:  Rosemary E Gale; Robert Hills; Arnold R Pizzey; Panagiotis D Kottaridis; David Swirsky; Amanda F Gilkes; Elizabeth Nugent; Kenneth I Mills; Keith Wheatley; Ellen Solomon; Alan K Burnett; David C Linch; David Grimwade
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.